Status:
RECRUITING
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases
Lead Sponsor:
Occlutech International AB
Conditions:
Muscular Ventricular Septal Defect
Eligibility:
All Genders
3-80 years
Brief Summary
The Occlutech® mVSD is indicated for percutaneous occlusion of hemodynamically or clinically significant muscular ventricular septal defects. The objectives of the study are: * To confirm the effica...
Detailed Description
This is a multicenter, prospective, and retrospective, international, post-market clinical follow-up Study to monitor the efficacy and safety of the Occlutech mVSD in patients with muscular ventricula...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
March 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05329350
Start Date
March 3 2022
End Date
October 1 2029
Last Update
February 2 2026
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Health Ireland
Dublin, Ireland, N512
2
İzmir Şehir Hastanesi
Izmir, Bayraklı, Turkey (Türkiye), 35540
3
Eskişehir Osmangazi Üniversite Hastanesi
Eskişehir, Odunpazarı, Turkey (Türkiye), 26040
4
Dicle Üniversitesi Tıp Fakültesi Hastanesi
Diyarbakır, Sur, Turkey (Türkiye)